-
2
-
-
77957344572
-
Healing the syk through kinase inhibitors
-
Rivera J, Colbert RA. Healing the Syk through kinase inhibitors. N Engl J Med 2010; 363:1362-4.
-
(2010)
N Engl J Med
, vol.363
, pp. 1362-1364
-
-
Rivera, J.1
Colbert, R.A.2
-
3
-
-
33645867986
-
A novel spleen tyrosine kinase inhibitor blocks c-jun N-terminal kinase-mediated gene expression in synoviocytes
-
Cha HS, Boyle DL, Inoue T, Schoot R., Tak PP, Pine P, et al. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther 2006; 317:571-8.
-
(2006)
J Pharmacol Exp Ther
, vol.317
, pp. 571-578
-
-
Cha, H.S.1
Boyle, D.L.2
Inoue, T.3
Schoot, R.4
Tak, P.P.5
Pine, P.6
-
4
-
-
77952249386
-
Contribution of gut bacteria to the metabolism of the spleen tyrosine kinase (Syk) inhibitor R406 in cynomolgus monkey
-
Sweeny DJ, Li W, Grossbard E., Lau DT. Contribution of gut bacteria to the metabolism of the spleen tyrosine kinase (Syk) inhibitor R406 in cynomolgus monkey. Xenobiotica 2010; 40:415-23.
-
(2010)
Xenobiotica
, vol.40
, pp. 415-423
-
-
Sweeny, D.J.1
Li, W.2
Grossbard, E.3
Lau, D.T.4
-
5
-
-
77953742534
-
Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: Contribution of hepatic and gut bacterial processes to the overall biotransformation
-
Sweeny DJ, Li W, Clough J., Bhamidipati S, Singh R, Park G., et al. Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation. Drug Metab Dispos 2010; 38:1166-76.
-
(2010)
Drug Metab Dispos
, vol.38
, pp. 1166-1176
-
-
Sweeny, D.J.1
Li, W.2
Clough, J.3
Bhamidipati, S.4
Singh, R.5
Park, G.6
-
6
-
-
77957333252
-
An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis
-
Weinblatt ME, Kavanaugh A, Genovese M.C., Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010; 363:1303-12.
-
(2010)
N Engl J Med
, vol.363
, pp. 1303-1312
-
-
Weinblatt, M.E.1
Kavanaugh, A.2
Genovese, M.C.3
Musser, T.K.4
Grossbard, E.B.5
Magilavy, D.B.6
-
7
-
-
55849114400
-
Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial
-
Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian A.H., Medrano-Ramirez G, Morales-Torres JL, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008; 58:3309-18.
-
(2008)
Arthritis Rheum
, vol.58
, pp. 3309-3318
-
-
Weinblatt, M.E.1
Kavanaugh, A.2
Burgos-Vargas, R.3
Dikranian, A.H.4
Medrano-Ramirez, G.5
Morales-Torres, J.L.6
-
8
-
-
78650294662
-
An oral syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents
-
Genovese MC, Kavanaugh A, Weinblatt M.E., Peterfy C., DiCarlo J, White ML, et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 2011; 63:337-45.
-
(2011)
Arthritis Rheum
, vol.63
, pp. 337-345
-
-
Genovese, M.C.1
Kavanaugh, A.2
Weinblatt, M.E.3
Peterfy, C.4
DiCarlo, J.5
White, M.L.6
-
9
-
-
0029044362
-
American college of rheumatology. Preliminary definition of improvement in rheumatoid arthritis
-
Felson DT, Anderson JJ, Boers M, Bombardier C., Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38:727-35.
-
(1995)
Arthritis Rheum
, vol.38
, pp. 727-735
-
-
Felson, D.T.1
Anderson, J.J.2
Boers, M.3
Bombardier, C.4
Furst, D.5
Goldsmith, C.6
-
10
-
-
0033984107
-
How to read radiographs according to the sharp/van der heijde method
-
van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000; 27:261-3.
-
(2000)
J Rheumatol
, vol.27
, pp. 261-263
-
-
Van Der Heijde, D.1
-
11
-
-
0036227149
-
How to report radiographic data in randomized clinical trials in rheumatoid arthritis: Guidelines from a roundtable discussion
-
van der Heijde D, Simon L, Smolen J, Strand V, Sharp J, Boers M, et al. How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion. Arthritis Rheum 2002; 47:215-8.
-
(2002)
Arthritis Rheum
, vol.47
, pp. 215-218
-
-
Van Der Heijde, D.1
Simon, L.2
Smolen, J.3
Strand, V.4
Sharp, J.5
Boers, M.6
-
12
-
-
33645762226
-
A sharper bonferroni procedure for multiple tests of significance
-
Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988; 75:800-2.
-
(1988)
Biometrika
, vol.75
, pp. 800-802
-
-
Hochberg, Y.1
-
14
-
-
0001669953
-
A comparison of two modified bonferroni procedures
-
Hommel G. A comparison of two modified Bonferroni procedures. Biometrika 1989; 76:624-5.
-
(1989)
Biometrika
, vol.76
, pp. 624-625
-
-
Hommel, G.1
-
15
-
-
84908309209
-
OSKIRA-2: A phase III, multicenter, randomized, double-blind, placebo-controlled parallel-group study of 2 dosing regimens of fostamatinib in rheumatoid arthritis patients with an inadequate response to disease-modifying antirheumatic drugs [abstract]
-
Dawes P, Dimic A, Genovese M., van der Heijde D, Jenkins M, O'Brien C, et al. OSKIRA-2: a phase III, multicenter, randomized, double-blind, placebo-controlled parallel-group study of 2 dosing regimens of fostamatinib in rheumatoid arthritis patients with an inadequate response to disease-modifying antirheumatic drugs [abstract]. Arthritis Rheum 2013; 65 Suppl 10:S198.
-
(2013)
Arthritis Rheum
, vol.65
, pp. S198
-
-
Dawes, P.1
Dimic, A.2
Genovese, M.3
Van Der Heijde, D.4
Jenkins, M.5
O'Brien, C.6
-
16
-
-
84954349338
-
OSKIRA-4: A phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy
-
Jul 29 (E-pub ahead of print)
-
Taylor PC, Genovese MC, Greenwood M, Ho M., Nasonov E, Oemar B, et al. OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. Ann Rheum Dis 2014 Jul 29 (E-pub ahead of print).
-
(2014)
Ann Rheum Dis
-
-
Taylor, P.C.1
Genovese, M.C.2
Greenwood, M.3
Ho, M.4
Nasonov, E.5
Oemar, B.6
-
17
-
-
84912051613
-
Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
-
in press
-
Weinblatt ME, Genovese MC, Ho M, Hollis S., Rosiak-Jedrychowicz K, Kavanaugh A, et al. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2014; in press.
-
(2014)
Arthritis Rheum
-
-
Weinblatt, M.E.1
Genovese, M.C.2
Ho, M.3
Hollis, S.4
Rosiak-Jedrychowicz, K.5
Kavanaugh, A.6
|